Taysha Gene Therapies
TSHA
TSHA
150 hedge funds and large institutions have $865M invested in Taysha Gene Therapies in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 61 increasing their positions, 34 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
1% more funds holding
Funds holding: 148 → 150 (+2)
23.05% less ownership
Funds ownership: 120.04% → 96.99% (-23%)
Holders
150
Holding in Top 10
4
Calls
$1.66M
Puts
$813K
Top Buyers
| 1 | +$15.4M | |
| 2 | +$10M | |
| 3 | +$9.16M | |
| 4 |
VPC
Vestal Point Capital
New York
|
+$8.18M |
| 5 |
Morgan Stanley
New York
|
+$7.99M |
Top Sellers
| 1 | -$26.7M | |
| 2 | -$11.5M | |
| 3 | -$9.17M | |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$7.43M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.82M |
